SK Biopharmaceuticals Initiates Clinical Development Program for Cenobamate in Asia

    Phase 3 clinical trial to support registrational filings in China and Japan

    Company on track to expand presence in Asia, reflecting its commitment to reach more people with epilepsy worldwide

    PANGYO, GYEONGGI PROVINCE, Korea, Sept. 12, 2020 /PRNewswire/ -- SK Biopharmaceuticals, Co., Ltd., a global innovative pharmaceutical company, announced plans to initiate a Phase 3 clinical trial for cenobamate in Asia, in line with the company's planned expansion beyond the U.S., where the drug is approved as a treatment for partial-onset seizures in adults.

    The trial will be initiated in Korea following the Korean Ministry of Food and Drug Safety's (MFDS) acceptance of the company's Investigational New Drug (IND) application for the trial on September 9, 2020. More than 500 patients from China, Japan and Korea are expected to be enrolled in the Phase 3 clinical trial.

    In China on September 9, the company received approval to initiate the Phase 3 trial as well as a separate Phase 1 clinical trial from China's National Medical Products Administration (NMPA), after submitting its Clinical Trial Application (CTA) in June 2020. SK Biopharmaceuticals also plans to submit a Clinical Trial Notification (CTN) for the Phase 3 trial to Japan's Pharmaceuticals and Medical Devices Agency (PMDA), under the wing of the Ministry of Health, Labour and Welfare, in October 2020.

    "The initiation of the Phase 3 clinical trial in Asia is a major milestone for cenobamate in our continuous effort to address unmet needs in epilepsy and central nervous system disorders worldwide," said Jungshin Park, vice president of SK Biopharmaceuticals' drug development business. "SK Biopharmaceuticals has been planning to enter Asian markets after launching our anti-seizure medication in the U.S. and forming a partnership for commercialization in Europe. We are pleased to move forward as intended to expand our global footprint."

    The Phase 3 trial is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of cenobamate as an adjunctive therapy in subjects with partial-onset seizures, with an optional open-label extension.

    About Cenobamate
    Cenobamate was discovered and developed by SK Biopharmaceuticals and SK life science. While the precise mechanism by which cenobamate exerts its therapeutic effect is unknown, it is believed to reduce repetitive neuronal firing by inhibiting voltage-gated sodium currents. It is also a positive allosteric modulator of the γ–aminobutyric acid (GABAA) ion channel.

    Cenobamate is approved in the United States as an anti-seizure medication (ASM) for the treatment of partial-onset seizures in adults, and is available under the brand name XCOPRI® (cenobamate tablets) CV. In early 2019, SK Biopharmaceuticals entered into an exclusive licensing agreement with Arvelle Therapeutics GmbH to develop and commercialize cenobamate in Europe.

    IMPORTANT SAFETY INFORMATION AND INDICATION FOR XCOPRI® (cenobamate tablets) CV

    DO NOT TAKE XCOPRI IF YOU:

    • Are allergic to cenobamate or any of the other ingredients in XCOPRI.
    • Have a genetic problem (called Familial Short QT syndrome) that affects the electrical system of the heart.

    XCOPRI CAN CAUSE SERIOUS SIDE EFFECTS, INCLUDING:

    Allergic reactions: XCOPRI can cause serious skin rash or other serious allergic reactions which may affect organs and other parts of your body like the liver or blood cells. You may or may not have a rash with these types of reactions. Call your healthcare provider right away and go to the nearest emergency room if you have any of the following: swelling of your face, eyes, lips, or tongue, trouble swallowing or breathing, a skin rash, hives, fever, swollen glands, or sore throat that does not go away or comes and goes, painful sores in the mouth or around your eyes, yellowing of your skin or eyes, unusual bruising or bleeding, severe fatigue or weakness, severe muscle pain, frequent infections, or infections that do not go away. Take XCOPRI exactly as your healthcare provider tells you to take it. It is very important to increase your dose of XCOPRI slowly, as instructed by your healthcare provider.

    QT shortening: XCOPRI may cause problems with the electrical system of the heart (QT shortening). Call your healthcare provider if you have symptoms of QT shortening including fast heartbeat (heart palpitations) that last a long time or fainting.

    Suicidal behavior and ideation: Antiepileptic drugs, including XCOPRI, may cause suicidal thoughts or actions in a very small number of people, about 1 in 500. Call your health care provider right away if you have any of the following symptoms, especially if they are new, worse, or worry you: thoughts about suicide or dying; attempting to commit suicide; new or worse depression, anxiety, or irritability; feeling agitated or restless; panic attacks; trouble sleeping (insomnia); acting aggressive; being angry or violent; acting on dangerous impulses; an extreme increase in activity and talking (mania); or other unusual changes in behavior or mood.

    Nervous system problems: XCOPRI may cause problems that affect your nervous system. Symptoms of nervous system problems include: dizziness, trouble walking or with coordination, feeling sleepy and tired, trouble concentrating, remembering, and thinking clearly, and vision problems. Do not drive, operate heavy machinery, or do other dangerous activities until you know how XCOPRI affects you.

    Do not drink alcohol or take other medicines that can make you sleepy or dizzy while taking XCOPRI without first talking to your healthcare provider.

    DISCONTINUATION:

    Do not stop taking XCOPRI without first talking to your healthcare provider. Stopping XCOPRI suddenly can cause serious problems. Stopping seizure medicine suddenly in a patient who has epilepsy can cause seizures that will not stop (status epilepticus).

    DRUG INTERACTIONS:

    XCOPRI may affect the way other medicines work, and other medicines may affect how XCOPRI works. Do not start or stop other medicines without talking to your healthcare provider. Tell healthcare providers about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.

    PREGNANCY AND LACTATION:

    XCOPRI may cause your birth control medicine to be less effective. Talk to your health care provider about the best birth control method to use.

    Talk to your health care provider if you are pregnant or plan to become pregnant. It is not known if XCOPRI will harm your unborn baby. Tell your healthcare provider right away if you become pregnant while taking XCOPRI. You and your healthcare provider will decide if you should take XCOPRI while you are pregnant. If you become pregnant while taking XCOPRI, talk to your healthcare provider about registering with the North American Antiepileptic Drug (NAAED) Pregnancy Registry. The purpose of this registry is to collect information about the safety of antiepileptic medicine during pregnancy. You can enroll in this registry by calling 1-888-233-2334 or go to www.aedpregnancyregistry.org.  

    Talk to your health care provider if you are breastfeeding or plan to breastfeed. It is not known if XCOPRI passes into breastmilk. Talk to your healthcare provider about the best way to feed your baby while taking XCOPRI.

    COMMON SIDE EFFECTS:
    The most common side effects in patients taking XCOPRI include dizziness, sleepiness, headache, double vision, and feeling tired.

    These are not all the possible side effects of XCOPRI. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.  

    DRUG ABUSE:

    XCOPRI is a federally controlled substance (CV) because it can be abused or lead to dependence. Keep XCOPRI in a safe place to prevent misuse and abuse. Selling or giving away XCOPRI may harm others and is against the law.

    INDICATION:
    XCOPRI is a prescription medicine used to treat partial-onset seizures in adults 18 years of age and older.

    It is not known if XCOPRI is safe and effective in children under 18 years of age.

    Please see additional patient information in the Medication Guide. This information does not take the place of talking with your healthcare provider about your condition or your treatment.

    Please see full Prescribing Information.

    About SK Biopharmaceuticals Co., Ltd. and SK Life Science, Inc.
    SK Biopharmaceuticals and its U.S. subsidiary SK life science are global pharmaceutical companies focused on the research, development and commercialization of treatments for disorders of the central nervous system (CNS). The companies have a pipeline of eight compounds in development for the treatment of CNS disorders, including epilepsy. Additionally, SK Biopharmaceuticals is focused on early research in oncology. For more information, visit SK Biopharmaceuticals' website at www.skbp.com/eng and SK life science's website at www.SKLifeScienceInc.com.

    Both SK Biopharmaceuticals and SK life science are part of SK Group, one of the largest conglomerates in Korea. SK Holdings, the parent company of SK Biopharmaceuticals, continues to enhance its portfolio value by executing long-term investments with a number of competitive subsidiaries in various business areas, including pharmaceuticals and life science, energy and chemicals, information and telecommunication, and semiconductors. In addition, SK Holdings is focused on reinforcing its growth foundations through profitable and practical management based on financial stability, while raising its enterprise value by investing in new future growth businesses. For more information, please visit http://hc.sk.co.kr/en/.

    XCOPRI® is a registered trademark of SK Biopharmaceuticals Co., Ltd.

    Media Contacts:

    Asia-Pacific Media Inquiries
    SK Biopharmaceuticals Co., Ltd.
    Hyongki Park
    [email protected]

    U.S. Media Inquiries
    SK Life Science, Inc.
    [email protected]

    Logo - https://mma.prnasia.com/media2/821937/SK_Biopharmaceuticals_Logo.jpg?p=medium600

     

    Related Links :

    https://www.skbp.com/eng.do

    Caishen.Co - Primary Data for China Secondary Investment and Stock Markets
    PR Newswire
    PR Newswire is the premier global provider of news release distribution and multimedia platforms that enable marketers, corporate communicators, sustainability officers, public affairs and investor relations officers to leverage content to engage with all their key audiences. Having pioneered the commercial news distribution industry since 1954, PR Newswire today provides end-to-end solutions to produce, optimize and target content – from rich media to online video to multimedia – and then distribute content and measure results across traditional, digital, mobile and social channels. Combining the world's largest multi-channel distribution and optimization network with comprehensive workflow tools and platforms, PR Newswire powers the stories of organizations around the world. PR Newswire serves tens of thousands of clients from offices in the Americas, Europe, Middle East, Africa and the Asia-Pacific region, and is a Cision company.